|Other Names||Cadherin-11, OSF-4, Osteoblast cadherin, OB-cadherin, CDH11|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP2772b was selected from the C-term region of human CDH11. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types.|
|Cellular Location||Cell membrane; Single-pass type I membrane protein|
|Tissue Location||Expressed mainly in brain but also found in other tissues. Expressed in neuroblasts|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CDH11 is a type II classical cadherin from the cadherin superfamily, integral membrane proteins that mediate calcium-dependent cell-cell adhesion. Mature cadherin proteins are composed of a large N-terminal extracellular domain, a single membrane-spanning domain, and a small, highly conserved C-terminal cytoplasmic domain. Type II (atypical) cadherins are defined based on their lack of a HAV cell adhesion recognition sequence specific to type I cadherins. Expression of this particular cadherin in osteoblastic cell lines, and its upregulation during differentiation, suggests a specific function in bone development and maintenance.
Chu,K., Mol. Cancer Res. 6 (8), 1259-1267 (2008)Tamura,D., Int. J. Oncol. 33 (1), 17-24 (2008)Getsios,S., Dev. Dyn. 211 (3), 238-247 (1998)
If you have any additional inquiries please email technical services at email@example.com.